Skip to main content
. 1998 May;66(5):2093–2098. doi: 10.1128/iai.66.5.2093-2098.1998

TABLE 3.

Anti-PRP and antitetanus antibody responses of infants receiving PncT, PncD, or placebo at 2, 4, and 6 months of agea

Country and mo (time related to dose) Anti-PRP antibodies
Antitetanus antibodies
GMC (μg/ml)
% with concn ≥1.0 μg/ml
GMC (mIU/ml)
% with concn ≥1.0 μg/ml
PncT PncD Placebo PncT PncD Placebo PncT PncD Placebo PncT PncD Placebo
Israel
 2 (pre) 0.17 0.36 0.20 13 28 8 0.08 0.12 0.21 0 13 4
 4 (post 1) 0.18 0.23 0.30 8 14 26 0.06 0.07 0.09 5 0 0
 6 (post 2) 0.86b 1.19b 2.95b 44 64 74 0.26 0.24 0.25 16 10 13
 7 (post 3) 2.81c 4.62c 6.62c 83 91 96 1.85 2.08 1.75 61 74 71
Finland
 2 (pre) 0.07 0.08 0.12 0 4 4 0.65 0.60 0.54 33 28 22
 4 (post 1) 0.09 0.09 0.11 0 4 6 0.31 0.29 0.26 8 8 1
 6 (post 2) 0.93 1.64 1.51 56 68 67 0.60 0.67 0.50 32 28 22
 7 (post 3) 7.18 12.50 11.0 92 100 96 3.49 3.99 4.27 96 96 96
Booster (Israel)
 12 (prebooster) 0.55d 1.44d 1.37d 24 64 71 0.36 0.42 0.24 12 9.5 0
 13 (postbooster) 10.95e 20.13e 20.84e 96 100 100 4.37 6.94 4.95 100 100 96
a

Each group contained 25 subjects, except for the Finnish placebo group, which contained 50 subjects. 

b

P = 0.0085 among the three groups. 

c

P = 0.0218 among the three groups. 

d

P = 0.0052 among the three groups. 

e

P = 0.076 among the three groups.